Clinical Study


Posted Date: Sep 7, 2020

  • Investigator: Thomas Herzog
  • Specialties: Cancer, Ovarian Cancer
  • Type of Study: Drug

This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). The primary outcomes of this study are determining the incidences of DLTs, progression free survival, and overall survival.


To Be Eligible: Must Have High Grade, Recurrent, Platinum Resistant Overian Cancer, Measurable Disease, Ecog 0-2, Adequate Organ Function, No Prior Organ Transplant, No Anticancer Therapy Within 3 Weeks, No Previous Rt To Abdomen Or Pelvis, No Significant Liver Disease, No Other Malignancy Within 3 Years, No Significant Active Or Past Medical History That May Impair Participants Ability To Adhere To Study Treatment


Ovarian Cancer, Peritoneal Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.